Radioimmunotherapy using .alpha.-particles emission
CA 2034484 C · Owner: Kaspersen, Franciscus M. · Inventors: Geerlings, Maurits W.; Kaspersen, Franciscus M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relate to the use of Actinium or one of its daughters in radioimmunotherapy. Also provided are immunoconjugates comprising an isotope a chelating agent and a slowly , localizing antibody. The invention also includes pharma ceutical compositions comprising said immunoconjugates as well as such , compositions comprising one or more scavenging agents. The compositions according to the invention are particularly useful for the treatment of micrometastases in adjuvant therapy. as well as for treatment of localized tumors.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 19, 1990 and granted August 15, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 19, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 19, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.